RxDoctor Payments Data

Rachel Majerus, APRN

Nurse Practitioner · Norfolk, NENPI 1437763042

Payments from drug & device makers

$666in general payments, 2019–2025

Across 40 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$146
  • Teva Pharmaceuticals USA, Inc.$114
  • Johnson & Johnson$105
  • Otsuka America Pharmaceutical, Inc.$99
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • Alkermes, Inc.$55
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$666 in reported general payments places this provider in the 65th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$24,379
Medicare patients
43
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$236,376
Invega SustennaPaliperidone Palmitate36$124,987
AustedoDeutetrabenazine23$121,282
Abilify MaintenaAripiprazole23$69,092
VraylarCariprazine Hcl37$59,528
Lurasidone Hcl38$15,925
Aripiprazole117$7,994
Paliperidone ErPaliperidone29$5,166
Desvenlafaxine Succinate ErDesvenlafaxine Succinate48$4,787
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine39$4,229
Clozapine28$1,718
Lamotrigine133$1,711
Vilazodone Hcl16$1,679
Quetiapine Fumarate ErQuetiapine Fumarate32$1,631
Clonazepam96$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$32$236,37629 claims
Johnson & JohnsonInvega Sustenna$105$124,98736 claims
Teva Pharmaceuticals USA, Inc.Austedo$114$121,28223 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$99$69,09223 claims
AbbVieVraylar$146$59,52837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →